The results of the ODYSSEY Outcomes trial of Alirocumab (Praluent) were presented today at the American College of Cardiology Scientific sessions. Alirocumab is an injectable antibody PCSK9 inhibitor that has been shown to significantly reduce LDL-cholesterol levels in prior trials.
ODYSSEY was … VIEW ARTICLE
For 30 years, we have had effective treatment to reduce the risk for early heart disease that has devastated FH families for generations. Yet, as a healthcare system, we have failed to ensure that individuals with familial hypercholesterolemia (FH) are properly diagnosed and treated.
In order to address one of … VIEW ARTICLE
In recognition of Heart Month, two FH Advocates for Awareness, hit the gym. But this time, not to work out but to spread awareness of familial hypercholesterolemia (FH). Gwynne and Mel spent the morning sharing information about FH with their fellow health club members in West Chester, PA.
As FH is very common, it … VIEW ARTICLE